NehaJadejaPagidipatiMD

Cardiology • Durham, NC

Preventive Cardiology

Physician

Join to view full profile

Dr. Pagidipati is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pagidipati's full profile

Already have an account?

Office
2301 Erwin Rd
Durham, NC 27705
Phone+1 919-681-9660

Education & Training

Duke University HospitalFellowship, Cardiovascular Disease, 2013 - 2017
Brigham and Women's HospitalResidency, Internal Medicine, 2008 - 2011
Harvard Medical SchoolClass of 2008

Certifications & Licensure

NC State Medical License 2013 - 2025
MA State Medical License 2011 - 2014
American Board of Internal Medicine Cardiovascular Disease

Clinical Trials

RESILIENCE: Personalizing Cardiovascular Health Start of enrollment: 2020 Sep 22
Completed
Not Applicable

Publications & Presentations

PubMed

Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics.
Adam J Nelson, Lisa A Kaltenbach, Darren K McGuire, Monica Levya, Hussein R Al-Khalidi
American Heart Journal. 2025-04-01
Air pollution, coronary artery disease, and cardiovascular events: Insights from the PROMISE trial.
Marcel C Langenbach, Thomas Mayrhofer, Isabel L Langenbach, Michael T Lu, Julia Karady
Journal of Cardiovascular Computed Tomography. 2025-03-18
Advancement of the Implementation of Evidence-based Therapies for Cardiovascular-Kidney-Metabolic Conditions: A Multi-Stakeholder Perspective.
Nkiru Osude, Harriette Van Spall, Hayden Bosworth, Konstantin Krychtiuk, John Spertus
American Heart Journal. 2025-03-17

Authored Content

Reducing Cardiovascular Risk Following StrokeSeptember 2020
An Outcome Model Approach to Transporting a Randomized Controlled Trial Results to a Target PopulationMarch 2019

Press Mentions

Heart Patients Miss Key Cholesterol Goal, Study FindsJanuary 6th, 2025
JACC - Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR SubstudyNovember 20th, 2024
Updates from the SELECT Trial: Outcomes by Sex | ESC 2024August 30th, 2024
Join now to see all